From: NILCO biomarkers in breast cancer from Chinese patients
Breast cancer | Non-malignant | ||||
---|---|---|---|---|---|
Antigen | ER- (n=21) | ER+ (n=33) | TNBC (n=13) | P-value* | Hyperplasias (n=3) or Fibroadenomas(n=2) |
Notch1 | 2.6 (2.01-3.19) | 2.55 (1.9-3.19) | 2.43 (1.68-3.18) | 0.743 | 1.45 (1.04-1.86) |
Negative | 0 (0) | 0 (0) | 1 (7.69) | 0.194 | NA |
Positive | 21 (100) | 33 (100) | 12 (92.31) | 5 (100) | |
Notch4 | 1.67 (1–3.48) | 1.62 (1–2.9) | 1.36 (1–2.87) | 0.449 | 2 (1.23 - 2) |
Negative | 5 (25) | 5 (16.13) | 5 (41.67) | 0.204 | NA |
Positive | 15 (75) | 26 (83.87) | 7 (58.33) | 3 (100) | |
JAG1 | 1.23 (1–2.09) | 1.37 (1–3) | 1.23 (1–2.24) | 0.776 | 1.28 (1.11 - 2.28) |
Negative | 6 (28.57) | 9 (27.27) | 4 (30.77) | 0.972 | NA |
Positive | 15 (71.43) | 24 (72.73) | 9 (69.23) | 5 (100) | |
DLL4 | 3.16 (1.91 - 3.66) | 3.21 (2–3.87) | 2.85 (1.19 - 3.36) | 0.028 | 3.18 (2.59 - 3.68) |
Negative | NA | NA | NA | NA | NA |
Positive | 21 (100) | 33 (100) | 13 (100) | 5 (100) | |
Leptin | 2.69 (1–4) | 3.16 (1–4) | 1.5 (1–3.84) | 0.675 | 1 (1–1.24) |
Negative | 6 (28.57) | 10 (30.3) | 5 (38.46) | 0.820 | 3 (60) |
Positive | 15 (71.43) | 23 (69.7) | 8 (61.54) | 2 (40) | |
OB-R | 1.06 (1–2.3) | 1.11 (1–2.2) | 1.05 (1–2.27) | 0.924 | 1 (1–1.5) |
Negative | 7 (33.33) | 10 (30.3) | 5 (38.46) | 0.867 | 4 (80) |
Positive | 14 (66.67) | 23 (69.7) | 8 (61.54) | 1 (20) | |
IL-1R tI | 3.65 (2.55 - 4) | 3.72 (2.46 - 4) | 3.31 (1–4) | 0.027 | 3.99 (2.74 - 4) |
Negative | 7 (33.33) | 10 (30.3) | 5 (38.46) | 0.194 | NA |
Positive | 14 (66.67) | 23 (69.7) | 8 (61.54) | 4 (100) | |
VEGF | 3.74 (2.22 - 4) | 3.67 (2.64 - 4) | 3.77 (1.04 - 4) | 0.767 | 3.96 (3.74 - 4) |
Negative | NA | NA | NA | NA | NA |
Positive | 21 (100) | 33 (100) | 13 (100) | 5 (100) | |
VEGFR2 | 1 (1–2) | 1 (1–2) | 1 (1–2) | 0.506 | 1 (1–1.1) |
Negative | 15 (71.43) | 20 (60.61) | 9 (69.23) | 0.685 | 3 (60) |
Positive | 6 (28.57) | 13 (39.39) | 4 (30.77) | 2 (40) |